Intellia Therapeutics ( NTLA ) and Regeneron Pharmaceuticals recently expanded their CRISPR human gene editing partnership. The partnership initially focused on liver diseases. Also, the companies plan to expand their collaboration to CRISPR-based therapies for neurological and muscular diseases.